In a win for Re­gen­eron, No­var­tis' sy­ringe for AMD drug de­clared 'un­patentable'

Re­gen­eron has won a patent case against Swiss phar­ma gi­ant No­var­tis over the de­liv­ery sys­tem for its eye drug Eylea.

The US Patent Tri­al and Ap­peal Board ruled that No­var­tis’ pre-filled sy­ringe for in­ject­ing its eye med­ica­tion Lu­cen­tis was “un­patentable” and hand­ed the vic­to­ry to Re­gen­eron and its AMD drug Eylea.

In the ini­tial com­plaint in 2020, No­var­tis al­leged to the US In­ter­na­tion­al Trade Com­mis­sion that cer­tain pre-filled sy­ringes for the in­trav­it­re­al in­jec­tion, and ul­ti­mate­ly Re­gen­eron’s de­liv­ery sys­tem for Eylea, were in­fring­ing on No­var­tis’ patent. Re­gen­eron filed a pe­ti­tion to re­view No­var­tis’ claims in 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA